AbbVie (ABBV) is in discussions to acquire mental health therapeutics company Gilgamesh Pharmaceuticals, with a potential deal potentially valuing Gilgamesh at roughly $1B, Bloomberg’s Eyk Henning, Madison Muller, and Liana Baker report, citing people familiar with the matter. Talks are ongoing and could still be delayed or even fall apart, the authors note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie in discussions to buy Gilgamesh in $1B deal, Bloomberg reports
- Notable companies reporting before tomorrow’s open
- AbbVie’s Ubrogepant Study: A Potential Game-Changer for Menstrual Migraine
- AbbVie Advances Lutikizumab Study for Hidradenitis Suppurativa
- AbbVie’s Promising Study on Mirvetuximab Soravtansine for Platinum-Resistant Cancers